AUTHORS
Samar Alshammasi, MD, Maria Perusini, MD, Msc2, Andre C. Schuh Sr, BSc, MD, FRCPC3, Vikas Gupta, MD FRCP, FRCPath4, Dawn Maze Sr, MD5, Karen W.L. Yee Sr, MD FRCPC6, Aaron Schimmer, MD PhD7, Guillaume Richard-Carpentier Sr, MD8, Marta Davidson, PhD MD9, Aniket Bankar, MD, MSc, DM, MBBS10, Mark Minden Sr, MD PhD11, Steven Chan Sr, MD/PhD12, Hassan Sibai, MD, Msc, BSc13
AFFILIATIONS
1 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
3 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
5 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
7 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
8 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
9 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
10 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
11 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
12 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
13 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
ABSTRACT
Background: Pegaspargase (PEG) is a key component of pediatric-inspired regimens for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL), but toxicity is believed to increase with age, limiting its delivery in older patients. A trough asparaginase activity level of ≥0.1 IU/mL is widely accepted to define therapeutically adequate asparagine depletion. At our institution, adult and adolescent/young adult (AYA) patients receive a Princess Margaret (PM)-DFCI regimen in which PEG dosing is individualized rather than fixed: 50% reduction for hepatic dysfunction or steatosis, or BMI ≥30, omission of PEG during induction above age 70 (with a plan to reinitiate during intensification), and premedication prior to each dose. PEG was initially introduced in a 2018–2019 pilot program (Moreno M. et al. EHA 2020 Abstract EP407). After native Escherichia coli asparaginase became unavailable in late 2020, PEG 1,250 IU/m² became standard, with the dose quickly being reduced to 1,000 IU/m² q3w, once therapeutic drug monitoring (TDM) confirmed adequate activity in most patients. TDM was subsequently performed on days 14 and 21, with subsequent doses increased by 20% for activity <0.1 IU/mL, maintained for 0.1–0.5 IU/mL, and reduced by 20% for >0.5 IU/mL. This report expands on our prior pilot study.
Methods: Single-center retrospective study of 63 adult and AYA patients with ALL or mixed-phenotype acute leukemia (MPAL) on PEG-containing PM-DFCI therapy, from 2018–2023. PEG activity was evaluated during induction and the first intensification cycle. The primary endpoint was trough asparaginase activity ≥0.1 IU/mL. Secondary endpoints included toxicity, complete remission (CR), overall survival (OS), and progression-free survival (PFS; diagnosis to relapse or death), by Kaplan–Meier. Patients were grouped by the institutional starting dose at treatment initiation: higher-dose (1,250–1,500 IU/m²) vs reduced-dose (1,000 IU/m²), with 50% reduction for hepatic dysfunction/steatosis and BMI in both.
Results: Median age was 42 years (range, 18–77); 21 patients (33%) were aged ≥60 years and 9 (14%) were aged ≥70 years. Fifty-one of 63 patients (81%) had at least one quantifiable asparaginase activity level and were included in the analysis below. Among these 51 patients, 44 (86%) had at least one asparaginase activity level ≥0.1 IU/mL. The median maximum asparaginase activity was 0.29 IU/mL (IQR, 0.14–0.43). Rates were 31/34 (91%) among patients aged <60 years and 13/17 (76%) among those aged ≥60 years (P=.20).
Fifty patients could be assigned to a starting-dose group; 13 lacked an induction date. Of 28 higher-dose patients, 27 were evaluable, and of 22 reduced-dose patients 19 were evaluable. Age did not differ significantly between groups (median 41 vs 50 years; P=.65). Therapeutic asparaginase activity (≥0.1 IU/mL) was achieved in 25/27 patients (93%) receiving higher-dose PEG vs 14/19 patients (74%) receiving reduced-dose PEG (P=.11). Median maximum asparaginase activity was lower with reduced dosing (0.21 vs 0.35 IU/mL; P=.03).
Adverse events possibly related to PEG occurred in 27/63 (43%): thrombosis 12 (19%), hepatotoxicity 9 (14%), hypersensitivity 6 (10%), and pancreatitis 5 (8%). Events were less frequent in the reduced-dose group (5/22 [23%] vs 16/28 [57%]; P=.02), and with age ≥60 vs <60 years (24% vs 52%; P=.04). Toxicities were not graded systematically.
CR was achieved in 56/62 (90%) with no deaths within 60 days; 12 relapsed and 11 underwent alloHCT. Of 16 deaths, 4 occurred after alloHCT; the remaining 12 were due to relapse (8), other causes (3), and toxicity (1). At a median follow-up 4.8 years, 5-year OS was 71.1% (95% CI, 56.7%–81.5%) and 5-year PFS was 65.8% (52.0%–76.6%); median OS was not reached. Outcomes were comparable between starting-dose groups (3-year OS 78.6% vs 81.3%, P=.29; 3-year PFS 71.4% vs 72.1%, P=.38), although follow-up was shorter in the reduced-dose group (median 4.3 vs 6.0 years).
Conclusions: An individualized, TDM-guided PEG strategy maintained therapeutic asparaginase activity in 86% of evaluable patients (44/51), including 76% of those aged ≥60 (13/17), while permitting substantial dose reduction. Five-year OS was 71% at a median age of 42 years, and outcomes did not differ between starting-dose groups. Individualized, activity-guided dosing, rather than fixed dosing enables delivery of pediatric-inspired therapy to older adults without compromising long-term outcomes.
DISCLOSURES
Samar Alshammasi, MD: No relevant conflicts of interest to declare.